Core Viewpoint - Baytex Energy Corp. has initiated a cash tender offer for its outstanding 7.375% Senior Notes due 2032, utilizing proceeds from the divestiture of its U.S. Eagle Ford assets, while also planning to redeem its 8.500% Senior Notes due 2030 [1][2][18] Group 1: Tender Offer Details - The tender offer is for all US$575 million of the 2032 Senior Notes, with a total consideration of US$1,040 for each US$1,000 principal amount, which includes an early tender payment of US$40 [2][8] - The tender offer will expire on December 30, 2025, with an early tender date of December 12, 2025, for holders to receive the early tender payment [5][9] - Holders can withdraw their tendered notes until the withdrawal deadline of December 12, 2025 [6] Group 2: Redemption of 2030 Senior Notes - Baytex plans to issue a conditional notice of redemption for all US$759.44 million of its 8.500% Senior Notes due 2030, scheduled for December 22, 2025, contingent on the completion of the Eagle Ford Asset Sale [18] Group 3: Conditions and Management - The tender offer is contingent upon the successful completion of the Eagle Ford Asset Sale, expected to close in late 2025 or early 2026, subject to regulatory approvals [11] - RBC Capital Markets, LLC has been retained as the dealer manager for the tender offer, while Global Bondholder Services Corporation will act as the information and tender agent [14]

Core Points - Brunswick Corporation announced a tender offer to purchase up to $100,000,000 of its 5.100% Senior Notes due 2052 [1] - The total consideration for validly tendered notes includes a fixed spread over the yield of a reference U.S. Treasury Security and an early tender premium of $50.00 per $1,000 [2][3] - The offer will expire on December 11, 2025, unless extended or terminated earlier [1] Offer Details - The tender offer is for an aggregate principal amount of up to $100,000,000 of 5.100% Senior Notes, with a total outstanding amount of $300,000,000 [1] - The reference U.S. Treasury Security is due August 15, 2055, with a yield of 4.685% [1] - The fixed spread for the notes is 175 basis points [1] Eligibility and Conditions - Only holders who validly tendered their notes by the Early Tender Deadline of November 25, 2025, are eligible for the total consideration [2][3] - Withdrawal rights for the notes expired at the Early Tender Deadline [4] Management and Contact Information - Wells Fargo Securities, LLC is the dealer manager for the offer, and D.F. King & Co., Inc. is the depositary and information agent [5] - Investors can contact Wells Fargo Securities for inquiries regarding the offer [5]

Core Viewpoint - Rapala VMC Corporation has successfully completed a tender offer for its existing hybrid capital securities, with a significant portion of the securities being tendered for purchase, indicating strong participation from holders [2][4][5]. Group 1: Tender Offer Details - The tender offer was initiated for holders of existing capital securities with a nominal amount of EUR 30 million, and the expiration deadline was set for November 24, 2025 [2][4]. - A total of EUR 28.5 million of the existing capital securities were validly tendered by holders for purchase [4]. - The purchase price for the existing capital securities is set at EUR 20,700 for every EUR 20,000 in principal amount, with accrued and unpaid interest to be paid on accepted securities [6]. Group 2: Shareholder Participation - Viellard Migeon Et Compagnie Sa, the largest shareholder of Rapala VMC, participated in the tender offer by tendering EUR 7.2 million of its holdings [7]. Group 3: Future Actions - Rapala VMC intends to utilize a clean-up call option if the adjusted nominal amount of the existing capital securities falls to 25% or less of the total issued amount, with a separate notice to be published around the settlement date [8]. - The settlement date for the tender offer is expected to be November 27, 2025, at which point all purchased securities will be cancelled [6]. Group 4: Company Overview - Rapala VMC is recognized as the world's leading fishing tackle company, with a diverse brand portfolio and a significant distribution network [10]. - The company reported net sales of EUR 221 million in 2024 and operates manufacturing facilities in multiple countries, employing approximately 1,400 people [10].

Core Points - Keros Therapeutics, Inc. announced the final results of its cash tender offer to repurchase up to 10,950,165 shares of common stock at a fixed price of $17.75 per share, totaling approximately $194.4 million [1][3] - The tender offer expired on November 18, 2025, and was part of a larger $375 million capital return program [1] - A total of 17,712,262 shares were validly tendered, leading to a pro rata acceptance of shares at a final proration factor of approximately 62.30% [2][3] Company Overview - Keros is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß family of proteins [6] - The company is recognized for its understanding of TGF-ß proteins, which regulate the growth and maintenance of various tissues [6] - Keros' lead product candidate, KER-065, targets neuromuscular diseases, particularly Duchenne muscular dystrophy, while its advanced candidate, elritercept, addresses cytopenias in patients with myelodysplastic syndrome and myelofibrosis [6]

Accessibility StatementSkip Navigation WILMINGTON, Del., Nov. 18, 2025 /PRNewswire/ --Â DuPont (NYSE: DD) announced today the early results of its previously announced tender offer (the "Tender Offer") to purchase for cash up to $739,256,000 aggregate principal amount (the "Maximum Tender Amount") of its 5.419% Notes due 2048 issued on November 28, 2018 (the "2048 Notes"). The Tender Offer is being made pursuant to the terms and conditions set forth in the Offer to Purchase, dated November 3, 2025 (the "Off ...

Core Points - LAVA Therapeutics announced that approximately 87% of its outstanding common shares were validly tendered in the tender offer by XOMA Royalty Corporation, satisfying the minimum tender condition [1] - The subsequent offering period for LAVA shareholders to tender their shares will expire on November 20, 2025, and shares tendered during this period cannot be withdrawn [2] - LAVA intends to voluntarily delist its common shares from Nasdaq, contingent upon the completion of the acquisition by XOMA Royalty [3] Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships with Johnson & Johnson and Pfizer for specific cancer treatments [4]

Group 1 - The Total Return Securities Fund has filed a registration statement with the SEC for a rights offering, allowing shareholders to purchase additional shares at 85% of the net asset value (NAV) per share on the expiration date of December 5, 2025 [1] - Shareholders of record on November 14, 2025, will receive one non-transferable right for each share held, and those who fully exercise their rights may subscribe for additional shares not taken by other rights holders [1] - The Board plans to authorize a tender offer to buy back between 15% and 30% of the Fund's outstanding shares at a price of at least 98% of NAV, depending on the results of the rights offering [2] Group 2 - A registration statement on Form N-2 related to the securities has been filed with the SEC but is not yet effective, meaning the securities cannot be sold or offered until it becomes effective [3] - This press release serves informational purposes only and does not constitute an offer to purchase or solicit an offer to sell shares of the Fund's common stock [4] - If a tender offer is initiated, the Fund will file a Tender Offer Statement with the SEC, which will include important information regarding the terms and conditions of the tender offer [4]

Core Points - Cogna Educação S.A. has extended the expiration date of its cash tender offer for Vasta Platform Limited's Class A common shares to December 10, 2025 [1][2] - The extension is due to the need for additional time for the SEC to review the Tender Offer Documents, which has been impacted by the U.S. government shutdown [2] - As of the previous expiration date, approximately 96.3% of the outstanding shares had been validly tendered into the offer [3] Offer Details - The tender offer was initially announced on September 17, 2025, and has undergone amendments on September 24, 2025, and October 16, 2025 [1][4] - The offer price is set at U.S.$5.00 per Class A common share [1] - The offer is subject to the conditions outlined in the Offer to Purchase, which includes the satisfaction or waiver of all conditions [4] Agents Involved - D.F. King & Co., Inc. serves as the information agent for the offer [5] - Equiniti Trust Company, LLC is the tender agent for the offer [5] - Itau BBA USA Securities, Inc. acts as the dealer manager for the offer [5]

Core Viewpoint - Thomas J. Herzfeld Advisors, Inc. and Herzfeld Credit Income Fund, Inc. announced the final results of a cash tender offer to purchase up to 5% of its outstanding common shares at 97.5% of the Fund's net asset value as of October 15, 2025 [1][3]. Summary by Relevant Sections Tender Offer Details - The Fund offered to purchase up to 5% or 845,433 shares of its outstanding common shares [2]. - A total of 11,603,885 shares were properly tendered, with 845,433 shares to be purchased [2]. - The pro-ration factor for the tender offer was calculated at 7.2858%, meaning that only a portion of the shares tendered would be accepted [2][4]. - The purchase price for the shares accepted was set at $2.5935, which is equal to 97.5% of the Fund's NAV per share [2][3]. Company Background - Thomas J. Herzfeld Advisors, Inc. is an SEC-registered investment advisor established in 1984, specializing in investment analysis and account management in closed-end funds [6].

Core Points - Thomas J. Herzfeld Advisors, Inc. and Herzfeld Credit Income Fund, Inc. announced preliminary results of a cash tender offer to purchase up to 5% of its outstanding common shares at 97.5% of the Fund's net asset value as of October 15, 2025 [1][2] Group 1: Tender Offer Details - The tender offer amount was up to 5% or 845,433 shares, with 11,603,885 shares properly tendered [2] - The purchase price for properly tendered shares was set at $2.5935, which is equal to 97.5% of the Fund's NAV per share as of the close of trading on October 15, 2025 [2] - If the number of common shares tendered exceeds the amount offered, the Fund will purchase shares on a pro-rata basis [3] Group 2: Final Results Announcement - The results are based on preliminary information and are subject to adjustment, with final results expected to be announced around October 20, 2025 [4] Group 3: Company Background - Thomas J. Herzfeld Advisors, Inc. is an SEC-registered investment advisor founded in 1984, specializing in investment analysis and account management in closed-end funds [5]